ReviewSignal transduction and targeted therapy2026
Multiple organ dysfunction syndrome: molecular mechanisms and therapeutic strategies.
Review in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple organ dysfunction syndrome presents a significant challenge in clinical critical care, characterized by the progressive or simultaneous failure of two or more organ systems following severe insults such as infection, trauma, acute pancreatitis, shock, burns, or other major events. Recent advancements in research have deepened the understanding of organ dysfunction, with a shift toward investigating organ injury and organ-specific diseases. The pathogenesis of MODS is intricate and driven by dynamic interactions across multiple levels, including inflammatory responses, microcirculatory disruptions, coagulation abnormalities, cell death, DNA damage and the production of reactive oxygen species. Recent innovations in single-cell technologies, spatial omics and organoid models have opened new avenues for exploring intercellular signaling, targeting damaged tissues and advancing drug development. Current therapeutic approaches for MODS involve comprehensive strategies, such as aggressive management of underlying causes, organ support, modulation of immune and inflammatory responses, nutritional intervention and stabilization of the internal environment. Despite these efforts, mortality rates remain high, and therapeutic advancements have yet to yield optimal results. This highlights the urgent need for continued research to translate scientific discoveries into clinical breakthroughs. Further exploration of the disease's pathogenesis, identification of early diagnostic biomarkers and development of novel, effective treatments are crucial to improving treatment outcomes and reducing mortality in critically ill patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.